| 84 | 0 | 72 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 评价卡瑞利珠单抗治疗恶性肿瘤的临床疗效和安全性,并探讨综合药学照护的应用价值。方法 从2020年10月至2021年5月在肿瘤科住院患者中选取使用卡瑞利珠单抗治疗的28例肿瘤患者作为研究对象,随访截至2021年9月。主要终点为无进展生存期(PFS)和治疗相关不良反应(AEs),次要终点为疾病控制率(DCR)和客观缓解率(ORR)。结果 入组28例患者的近期疗效:有效率为75%,ORR为11%(3/28),DCR为75%(21/28);远期疗效:有效率为50%,ORR为11%(3/28),DCR为50%(14/28)。食管恶性肿瘤的中位PFS为(4.513±0.852)个月,肺恶性肿瘤的中位PFS为(4.921±0.991)个月。不同年龄、治疗前不同美国东部肿瘤合作组(ECOG)评分、有无基础疾病及治疗中有无出现反应性皮肤毛细血管增生症(RCCEP)患者的PFS差异有统计学意义(P <0.05)。AEs发生率为96.4%。患有基础疾病的患者和年龄> 65岁的患者更容易出现3级及以上AEs。结论 卡瑞利珠单抗治疗恶性肿瘤的临床疗效尚可,但AEs发生率较高。建议对使用卡瑞利珠单抗治疗的恶性肿瘤患者进行综合药学照护,以提高用药安全性。
Abstract：AIM To evaluate the clinical efficacy and safety of camrelizumab in treatment of malignant tumors and explore the application value of comprehensive pharmaceutical care. METHODS A total of 28 tumor patients hospitalized with camrelizumab treatment from October 2020 to May 2021 were selected as the study subjects and follow-up was up to September 2021. The primary endpoints were progression-free survival(PFS) and treatment-related adverse effects(AEs), while the secondary endpoints were disease control rate(DCR) and objective response rate(ORR). RESULTS In the 28 patients, recent efficacy: the response rate was 75%, ORR was 11%(3/28) and DCR was 75%(21/28), long-term efficacy: response rate was 50%, ORR was 11%(3/28) and DCR was 50%(14/28). The median PFS for oesophageal malignancy was(4.513 ± 0.852) months, and the median PFS for lung malignancy was(4.921 ± 0.991) months. There were significant differences in PFS for different ages, different Eastern Cooperative Oncology Group(ECOG) scores, presence of underlying disease, and patients with reactive cutaneous capillaries(RCCEP) under treatment(P < 0.05). The incidence of AEs in 28 patients was 96.4%. Patients with underlying diseases and those aged > 65 years were more likely to have grade 3 and above AEs. CONCLUSION The clinical efficacy of camrelizumab in the treatment of malignant tumors is reasonable, but the incidence of AEs is high. Comprehensive pharmaceutical care can be carried out for patients with malignant tumors treated with camrelizumab to improve safety.
[1]SIEGEL R, MILLER K, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1):7.
[2]SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209.
[3]HE M Y, YANG T, WANG Y H, et al. Immune checkpoint inhibitorbased strategies for synergistic cancer therapy[J]. Adv Healthc Mater, 2021, 10(9):e2002104.
[4]CHENG Y, WENG S S, YU L Z, et al. The role of hyperthermia in the multidisciplinary treatment of malignant tumors[J]. Integr Cancer Ther, 2019, 18:1534735419876345.
[5]HWANG K, YOON J H, LEE J H, et al. Recent advances in monoclonal antibody therapy for colorectal cancers[J].Biomedicines, 2021, 9(1):39.
[6]秦叔逵,马军,李进,等.卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识[J].临床肿瘤学杂志, 2020, 25(9):840.
[7]佘明金.卡瑞利珠单抗治疗恶性肿瘤的临床研究进展[J].癌症进展, 2020, 18(9):865.
[8]LAN C Y, SHEN J X, WANG Y, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer(CLAP):a multicenter,open-label, single-arm, phase II trial[J]. J Clin Oncol, 2020,38(34):4095.
[9]XIAO L, ZHANG Y, LIN Q. 442P Camrelizumab combined with apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer:one-arm exploratory clinical trial[J]. Ann Oncol, 2020, 31:S429.
[10]XIA L, ZHOU Q, ZHANG Y, et al. 840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer:an open-label, multicenter phase II study[J]. Ann Oncol, 2020, 31:S630.
[11]BUDLONG H, BRUMMEL A, RHODES A, et al. Impact of comprehensive medication management on hospital readmission rates[J]. Popul Health Manag, 2018, 21(5):395.
[12]ISETTS B J, SCHONDELMEYER S W, ARTZ M B, et al. Clinical and economic outcomes of medication therapy management services:the Minnesota experience[J]. J Am Pharm Assoc,2008, 48(2):203.
[13]BRAHMER J R, LACCHETTI C, SCHNEIDER B J, et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:American society of clinical oncology clinical practice guideline[J]. J Clin Oncol,2018, 36(17):1714.
[14]YANG Y P, QU S, LI J G, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma(CAPTAIN-1st):a multicentre, randomised, double-blind, phase 3 trial[J].Lancet Oncol, 2021, 22(8):1162.
[15]ZHOU C C, CHEN G Y, HUANG Y C, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer(CameL):a randomised, open-label,multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3):305.
[16]李秦川,刘春,叶永琴.基于药物治疗管理服务的综合药学照护模式初探[J].中国药师, 2019, 22(2):291.
[17]王鹏,王晶,王建英.卡瑞利珠单抗致血压升高1例[J].浙江实用医学, 2020, 25(5):380.
[18]王金爽,韩正祥.抗血管生成靶向药物治疗肿瘤引起高血压的机制及研究进展[J].现代肿瘤医学, 2018, 26(5):800.
[19]WIT M D, BOERS-DOETS C B, SAETTINI A, et al. Prevention and management of adverse events related to regorafenib[J].Support Care Cancer, 2014, 22(3):837.
基本信息:
DOI：10.19577/j.1007-4406.2023.07.001
中图分类号:R969
引用信息:
[1]李秦川,阳玉飞,陈岷.基于卡瑞利珠单抗治疗恶性肿瘤的临床疗效和安全性探讨综合药学照护的应用价值[J].中国临床药学杂志,2023,32(07):481-486.DOI:10.19577/j.1007-4406.2023.07.001.
基金信息:
中国药学会全国医药信息网2022年科普研究项目(编号CMEI2022KPYJ00501); 中国药科大学国家执业药师发展研究中心课题(编号ndrplc201903-3)
2023-07-25
2023-07-25